Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
RNS Hotlist with Zak Mir: HUI, ALK, POLB, HEMO, EML, MMAG, BVC, COBR, MBT, DVRG, BZT, KEFI, ATOM, OSI, ROQ, MEN & NCCL
Hydrogen Utopia International (HUI), a company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels, announced the admission of its shares today at 8am to the Official List of
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial
RNS Hotlist with Zak Mir: ORR, GCAT, ZPHR, POLB, COPL, HUI, OKYO, PRE, COOK, BLOE & THR via Vox Markets
We perhaps found out today why shares of Oriole Resources (ORR) have been such a firm market of late. The AIM-quoted gold exploration company reported that its partner IAMGOLD Corporation
Poolbeg Pharma PLC (AIM:POLB) identifies novel RSV drug candidates
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Share Talk Weekly Stock Market News Review, Sunday 18th December 2022
It is a cliché that the stock market runs in cycles. This is especially the case given that statistically, the markets spend as much as 80% of the time in
RNS Hotlist with Zak Mir: POLB, LIFE, MSMN, CGO, IOF, LOOP, BEM, MIRI, CODE, AET, CYAN & BILN via Vox Markets
Poolbeg Pharma (POLB), a biopharmaceutical company, announced that it has acquired an exclusive licence from InsuCaps Limited, a sister company of AnaBio Technologies, to use InsuCaps’ patented microencapsulation and nanoencapsulation
Poolbeg Pharma PLC (AIM:POLB) Metabolic diseases oral delivery licence signed
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS human challenge trial completed
POLB 001 LPS human challenge clinical trial successfully completed
RNS Hotlist with Zak Mir: POLB, HUI, AXL, ALL, AMRQ, NSCI, THR, WATT, COOK, PYX, GRX, AAU, KDR, JOG, ECO, ORCA, ORR, SOU & GCAT
Poolbeg Pharma (POLB), a clinical stage infectious disease pharmaceutical company, announced that, further to its announcement in March 2022, the construction of the computational artificial intelligence (AI) influenza disease model
Poolbeg Pharma PLC (AIM:POLB) Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023